Idiopathic Interstitial Pneumonias clinical trials
The registry lists 27 studies for Idiopathic Interstitial Pneumonias across more than 10 countries. 6 are recruiting or about to start. 13 of them are mainly about Idiopathic Interstitial Pneumonias (how this is decided). Per ClinicalTrials.gov, last updated 2026-08-20.
Get an email when these change. Save the Idiopathic Interstitial Pneumonias studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
FibroGen (3) · Cedars-Sinai Medical Center (2) · Royal College of Surgeons, Ireland (1) · University of California, Los Angeles (1) · National Jewish Health (1) · University of Virginia (1) · North East Japan Study Group (1) · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1)
What is being tested here
Drugs under test in Idiopathic Interstitial Pneumonias studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Zinc | 1 | 0 | 1 |
| Nicotinamide-beta-riboside | 1 | 0 | 1 |
| Pamrevlumab | 0 | 2 | 3 |
| FAPI-46 | 0 | 0 | 1 |
| Atezolizumab | 0 | 0 | 1 |
| Admilparant | 0 | 0 | 1 |
| Bardoxolone methyl | 0 | 0 | 1 |
| SC1011 | 0 | 0 | 1 |
| Belumosudil | 0 | 0 | 1 |
| CC-90001 | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Jan 2027Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis · Cedars-Sinai Medical Center
Who these studies take
Of the 5 Idiopathic Interstitial Pneumonias studies recruiting now, 4 (80%) set no upper age limit and 0 (0%) stop at 75 or younger. 2 (40%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (40%) | 2 (40%) |
| 18 | 4 (80%) | 4 (80%) |
| 30 | 4 (80%) | 4 (80%) |
| 40 | 4 (80%) | 4 (80%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 5 (100%) | 5 (100%) |
| 85 | 5 (100%) | 5 (100%) |
Across all 27 studies, recruiting or not: 7% stop at 75 or younger and 4% at 65; 15% take children; 0% are for women only and 0% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 27 of 27. search them.
- Interstitial Lung Disease: A Study From Infancy to Elderly Including RelativesRecruitingNCT060367191 country
- Zinc and Nicotinamide Riboside for Idiopathic Pulmonary FibrosisRecruitingNCT06567717Phase 21 country
- Precision Diagnosis and Care for Families With Pulmonary Fibrosis in IrelandRecruitingNCT067022281 country
- University of Virginia Natural History StudyEnrolling by invitationNCT048961381 country
- Deep Learning Diagnostic and Risk-stratification for IPF and COPDRecruitingNCT053185991 country
- Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT010882172 countries
- FAPI PET for Lung FibrosisActive, not recruitingNCT05365802Early Phase 11 country
- BPF Genetics of ILD StudyCompletedNCT037476271 country
- Atezolizumab for Idiopathic Pulmonary FibrosisActive, not recruitingNCT05515627Phase 11 country
- Japanese Idiopathic Interstitial Pneumonias RegistryActive, not recruitingNCT030416231 country
- A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisCompletedNCT04308681Phase 218 countries
- Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATCompletedNCT02036970Phase 22 countries
- Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective StudyCompletedNCT038364171 country
- The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.CompletedNCT06160440Phase 11 country
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Phase 39 countries
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Phase 325 countries
- Clinical Course of Interstitial Lung Diseases: European IPF Registry and BiobankActive, not recruitingNCT029514165 countries
- A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisTerminatedNCT03142191Phase 213 countries
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary FibrosisCompletedNCT02688647Phase 21 country
- The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial IntelligenceCompletedNCT051469341 country
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01890265Phase 27 countries
- Screening Microorganism of Cryptogenic Mechanical Pneumonia Through Next Generation Sequencing to Lung Tissue FluidStatus unknownNCT045118841 country
- Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-upStatus unknownNCT041790581 country
- Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung DiseaseCompletedNCT02594839Phase 1/21 country
- Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)TerminatedNCT02138825Phase 221 countries
- Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial PneumoniasCompletedNCT02596841
- Peripheral Blood Biomarkers in Idiopathic Interstitial PneumoniasTerminatedNCT011515271 country